Orally administrable protein / peptide-based therapeutics offer several advantages including, effective treatment of numerous clinical conditions and degenerative disorders. Interestingly, recent advances in this domain have led to the development of several treatment strategies that, according to developers, exhibit the necessary capabilities to overcome challenges posed by traditional oral protein formulations and peptide-based therapies. One of the key objectives behind the aforementioned developments is to overcome issues related to high costs associated with the design and production of such pharmacological interventions. However, it is important to highlight that there are still several challenges which need to be addressed in order to develop biologic drugs capable of effectively being administered via the oral route without undergoing significant losses in specificity and / or bioavailability. Over 40 oral drug delivery technologies have been designed so far. Owing to the numerous advantages of oral drug delivery, including ease of administration, minimal pain and risk of drug reaction, and self-administration, we are led to believe that the oral protein / peptide therapeutics market is anticipated to witness a significant growth in the coming future.
Pipeline Overview of Oral Peptide and Protein-based Therapeutics
With four commercialized therapies and over 120 clinical / preclinical development programs, oral protein and peptide therapies represent a lucrative segment of the pharmaceutical industry.
Clinical Research Landscape of Oral Peptide and Protein-based Therapeutics
Over 200 clinical trials focused on oral protein and peptides have been registered across the globe; majority of these trials are evaluating therapies intended for chronic constipation, diabetes and irritable bowel syndrome.
Oral Drug Development and Formulation Technologies are being Leveraged by Companies to Develop Novel Therapeutic Interventions
More than 40 innovative technology platforms are presently being leveraged by industry stakeholders for the development of oral proteins and peptides.
Intellectual Property Landscape of Orally Administrable Protein / Peptide-based Therapeutics
Over 300 patents have been granted / filed by academia and industry stakeholders in the last five years, exclusively for oral protein and peptides and associated delivery technologies.
The Oral Protein and Peptides Market is anticipated to grow at a CAGR of over 20%, during 2022-2032
Owing to the established potential of marketed drugs and anticipated approval of novel therapies the market opportunity associated with oral protein and peptide therapies is anticipated to witness an annualized growth of over 20% in the coming decade.
To get a detailed information on the drug pipeline, key opinion leaders, drug delivery technologies, market landscape, funding and investment trend, partnerships and collaborations, clinical trials activity, patent landscape, big pharma activity, key commercialization strategies adopted by companies and the likely market evolution kindly visit the link below
For further information on this domain, check out the report –